$2.04
5.42% day before yesterday
Nasdaq, Dec 01, 03:30 pm CET
ISIN
US14888D2080
Symbol
CSCI

Catalyst Biosciences, Inc. Stock price

$2.17
-0.34 13.40% 1M
-1.49 40.68% 6M
-0.61 21.84% YTD
-0.76 25.86% 1Y
-13.68 86.33% 3Y
-41.97 95.09% 5Y
-882.84 99.76% 10Y
-317,433.96 100.00% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
+0.13 6.13%
ISIN
US14888D2080
Symbol
CSCI
Industry

Key metrics

Basic
Market capitalization
$6.6m
Enterprise Value
$260.0k
Net debt
positive
Cash
$8.5m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | -
P/S
0.7 | -
EV/Sales
0.0 | -
EV/FCF
negative
P/B
1.3
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$9.1m | -
EBITDA
$-10.3m | -
EBIT
$-11.6m | -
Net Income
$-14.9m | -
Free Cash Flow
$-11.0m
Growth (TTM | estimate)
Revenue
41.6% | -
EBITDA
38.2% | -
EBIT
31.1% | -
Net Income
-4.9% | -
Free Cash Flow
38.4%
Margin (TTM | estimate)
Gross
45.1%
EBITDA
-113.7% | -
EBIT
-128.0%
Net
-164.6% | -
Free Cash Flow
-121.2%
Financial Health
Equity Ratio
37.5%
Return on Equity
-116.3%
ROCE
-58.3%
ROIC
-100.1%
Debt/Equity
0.4
More
EPS
$-4.7
FCF per Share
$-3.5
Short interest
0.3%
Employees
-
Rev per Employee
-
Show more

Is Catalyst Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Catalyst Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Catalyst Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
9.05 9.05
42% 42%
100%
- Direct Costs 4.97 4.97
37% 37%
55%
4.09 4.09
49% 49%
45%
- Selling and Administrative Expenses 10 10
2% 2%
115%
- Research and Development Expense 5.26 5.26
43% 43%
58%
-10 -10
38% 38%
-114%
- Depreciation and Amortization 1.29 1.29
892% 892%
14%
EBIT (Operating Income) EBIT -12 -12
31% 31%
-128%
Net Profit -15 -15
5% 5%
-165%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
TORONTO, ONTARIO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug Int...
Neutral
GlobeNewsWire
18 days ago
TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company's board of directors (the “Board”), has been appointed Interim Chief Executive Officer, effective immediately....
Neutral
GlobeNewsWire
4 months ago
COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq , while retaining the Company's listing on the TSX
More Catalyst Biosciences, Inc. News

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Ms. Biehn
Founded 1997
Website www.cosciensbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today